Why some patients with type 2 diabetes are protected against cardiovascular disease (CVD) has not been clarified. Toyohara et al. reveal that in patients protected from CVD, arylacetamide deacetylase (AADAC) is elevated in vascular smooth muscle cells (VSMCs). AADAC alters lipid metabolism and cellular processes in VSMCs and ameliorates CVD.
- cardiovascular disease, diabetes, induced pluripotent stem cell, disease modeling, lipid metabolism, cholesterol, Kennedy pathway, arylacetamide deacetylase, vascular smooth muscle cell, endothelial cell